Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-04-25
2006-04-25
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C554S065000
Reexamination Certificate
active
07034058
ABSTRACT:
The present invention provides an anti-tumor pharmaceutical composition having a high anti-tumor effect with low side-effects. The anti-tumor pharmaceutical composition comprises a N-vanillyl fatty acid amide of formula (1):wherein —CO—R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms. Accordingly the invention provides an anti-tumor pharmaceutical composition comprising a N-vanillyl fatty acid amide which relates to capsaicin wherein the composition has a low side-effect and a high anti-tumor effect, in particular an anti-melanoma effect and an anti-leukemia cell effect; and is very low pungent, stimulatory and preinflammatory effect.
REFERENCES:
patent: 4898887 (1990-02-01), Janusz et al.
patent: 5221692 (1993-06-01), Chen
patent: 6022718 (2000-02-01), Iwai et al.
patent: 2004/0122089 (2004-06-01), Martin et al.
patent: WO 00/16756 (2000-03-01), None
Janusz et al., J. Med. Chem. (1993), 36, pp. 2595-2604.
HCAPLUS, DN 141:99178, Jin et al., Nippon Shokuhin Kagaku Gakkaishi, 9(2), 50-53 (2002) abstract only.
HCAPLUS, DN 139:142982, Takahata et al., New Food Industry, 44(10), 6-12 (2002), abstract only.
Morre et al. “Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture”Proc. Nat;. Acad. Sci.USAvol. 92, pp. 1831-1835, Mar. 1995.
Takahata et al. “Growth Inhibition of capsaicin on hela cells is not mediated b intracellular calcium mobilization”Life Sciences, vol. 64, No. 13, pp. PL 165-171 (1999).
Szallasi et al. “Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor”LifeSciencesvol. 47, pp. 1399-1408 (1990).
Morre et al. “Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines”European Journal of Cancer, vol. 32A, No. 11, pp. 1995-2003, (1996).
Melck, et al., “Suppression of nerve Growth Factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation,” Endocrinology, vol. 141, No. 1, pp. 118-126 (2000) (Document No. XP-002272763).
Melck, et al., “Unsaturated long-chain N-Acyl-vanillyl-amindes (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to SB1 cannabinoid receptors,” Biochemical and Biophysical Research Communications, Academic Press Inc., vol. 9, No. 13, pp. 275-284 (Document No. XP-000892119).
Jacobsson, et al., “Inhibition of rat c6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors,” Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, vol. 299,No. 3, pp. 951-959 (2001) (Document No. XP-001120403).
De Petrovellis, et al. “Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders,” Chemistry and Physics of Lipids, vol. 108, pp. 191-209 (2000) (Document No. XP-002941399).
Di Marzo, et al., “Highly selective CB1cannabinoid receptor ligands and novel CB1/ VR1vanilloid receptor “hybrid” ligands,” Biochemical and Biophysical Research Communications, vol. 281, No. 2, pp. 444-451 (2001) (Document No. XP-002272764).
Takahata, et al., “Inducting effect of cancer cell apoptosis by docosahexaenoic acid (DHA) derivatives (Dohevanil) of a hot ingredient of red pepper, capsaisin,” New Food Industry, 44(10), 6-10, (2002) (Document No. XP-009026691) and English Translation Provided.
Keisuke, et al., “Homovanillic acid derivative, capsaisin, induces apoptosis of myeloid leukemic cel via a p53-dependent pathway in vitro and in vivo,” Database Accession No. PREV 200300368073, Blood, vol. 100, No. 11 (Nov. 16, 2002) pg. Abstract No. 4589, 44thAnnual Meeting of the American Society of Hematology: Philadelphia PA (Dec. 6-10, 2002) (Document No. XP-0022722766).
Patel, et al., “Capsaicin regulates vascular endothelial cell growth factor expression by modulation of hypoxia inducing factor-1α in human malignant melanoma cells,” J. Cancer Res Clin Oncol, vol. 128, pp. 461-468 (2002) (Document No. XP-002272765).
Di Marzo, et al., “Interactions between synthetic vanilloids and the endogenous cannabinoid system,” FEBS Letters, Elsevier Science Publishers, Amsterdam, NL., vol. 436,No. 3, pp. 449-454 (1998) (Document No. XP-004258472).
Sherwin, et al., “Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces,” Proc. Natl. Acad Sci. USA, vol. 76, No. 3, pp. 1288-1292 (1997) (Document No. XP-009026810).
De Cabo, et al., “Inhibition of growth and metastasis of B-16 mouse melanoma cells inhibited by capsaisin,” Molecular Biology of the cell, vol. 7, no. Suppl, p. 172A (1996) (Document No. XP-009026860).
Bozicevic Field & Francis LLP
Delacroix-Muirheid C.
Francis Carol L.
Kureha Corporation
Low Christopher S. F.
LandOfFree
Anti-tumor pharmaceutical composition comprising N-vanillyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tumor pharmaceutical composition comprising N-vanillyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor pharmaceutical composition comprising N-vanillyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3614478